Leucovorin and high-dose fluorouracil in metastatic prostate cancer: A phase II trial of the Piedmont Oncology Association

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 19, Issue 1, 1996, Pages 23-25

  Atkins, James N ^a   Muss, Hyman B ^a   Case, L Douglas ^a   Richards II, Frederick ^a   Grote, Thomas ^a   McFarland, James ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Chemotherapy; Fluorouracil; Leucovorin; Metastatic; Prostate

Indexed keywords

FLUOROURACIL; FOLINIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; HUMAN; INFECTION RISK; MALE; METASTASIS; NAUSEA; NEUROTOXICITY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PROSTATE CANCER; STOMATITIS; VOMITING;

AGED; AGED, 80 AND OVER; ANTIDOTES; ANTIMETABOLITES, ANTINEOPLASTIC; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 0030048023     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199602000-00005     Document Type: Article

References (12)

1. Nevin JE, Melnick I, Baggerly JT Jr, et al. The continuous arterial infusion of 5-fluorouracil as a therapeutic adjunct in the treatment of advanced carcinoma of the bladder and prostate. a preliminary report. Cancer 1973;31:138-44.
2. Nevin JE, Hoffman AA. Use of arterial infusion of 5-fluorouracil either alone or in combination with supervoltage radiation as a treatment for carcinoma of the prostate and bladder. Am J Surg 1975;130:544-9.
3. Gibbons RP. Cooperative clinical of single and combined agent protocols: adjuvant protocols. National Prostatic Cancer Project Cooperative Clinical Trials. Urology 1981;17:48-52.
4. Smalley RV, Bartolucci AA, Hemstreet G, Hester M. A phase II evaluation of a 3-drug combination of cyclophosphamide, doxorubicin and 5-fluorouracil and of 5-fluorouracil in patients with advanced bladder carcinoma or stage D prostatic carcinoma. J Urol 1981;125:191-5.
5. Spiers AS, Kasimis BS, Janis MG. High-dose intravenous infusions of 5-fluorouracil for refractory solid tumours-the HI-FU regimen. Clin Oncol 1980;6:63-9.
6. Citron M, Nathan K, Kalra J, et al. Phase I-II inpatient and outpatient study of 24-hour continuous infusion 5-fluorouracil for advanced cancers. Proc Am Soc Clin Oncol 1986;5:52 [Abstract].
7. Atkins JN, Muss HB, Case D, et al. High-dose 24-hour infusion of 5-fluorouracil in metastatic prostate cancer: a phase trial of the Piedmont Oncology Association. Am J Clin Oncol 1991;14: 526-29.
8. Seifert P, Baker LH, Reed ML, Vaitkevicius VK. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 1975;36:123-8.
9. Lokich J, Fine N, Perri J, Bothe A Jr. Protracted ambulatory venous infusion of 5-fluorouracil. Am J Clin Oncol 1983;6:103-7.
10. Decker DA, Drelichman A, Jacobs J, et al. Adjuvant chemotherapy with cis-diamminodichloroplatinum II and 120-hour infusion 5-fluorouracil in stage III and IV squamous cell carcinoma of the head and neck. Cancer 1983;51:1353-5.
11. Shah A, MacDonald W, Goldie J, et al. 5-FU infusion in advanced colorectal cancer: a comparison of three dose schedules. Cancer Treat Rep 1985;69:739-42.
12. Fraile RJ, Baker LH, Buroker TR, et al. Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Res 1980;40:2223-8.